Fulcrum therapeutics announces recent business highlights and financial results for the fourth quarter and full year 2022

― company is working to address clinical hold on the investigational new drug application for ftx-6058 for the potential treatment of sickle cell disease ―

FULC Ratings Summary

FULC Quant Ranking